Key Highlights

  • Clarity Pharmaceuticals (ASX:CU6), EBR Systems (ASX:EBR) and Doctor Care Anywhere (ASX:DOC) all traded lower during the 13 November 2026 session.
  • Clarity shares were down 8.42%, Doctor Care Anywhere 8.70% and EBR Systems 7.35%.
  • The three companies reported a regulatory designation, device implant progress and Revenue growth in their latest updates.

During the Trading session on 13 November 2026, Clarity Pharmaceuticals Ltd (ASX:CU6) shares were trading at $1.88, down 8.42%, EBR Systems Inc (ASX:EBR) shares were at $0.158, down 7.35%, and Doctor Care Anywhere Group PLC (ASX:DOC) shares were at $0.105, down 8.70%. The S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT over the same session.

Clarity Pharmaceuticals (ASX:CU6)

Clarity received FDA Breakthrough Therapy Designation for PET imaging of PSMA-positive lesions with Cu-64 SAR-bisPSMA, announced on 12 November 2026. Its Phase III AMPLIFY and CLARIFY trials have completed recruitment, with topline data expected in the first half of calendar 2027. The product is unregistered, and the company notes that fewer than half of designation requests are successful.

EBR Systems (ASX:EBR)

EBR completed 40 commercial WiSE System implants in the third quarter of 2026, taking total commercial implants to 157. Medicare inpatient reimbursement for eligible procedures increased from 1 October 2026, and a proposed National Coverage Determination decision is expected in early December.

Doctor Care Anywhere (ASX:DOC)

Doctor Care Anywhere reported third-quarter revenue of £11.3 million, up 16%, with subscriptions at 19% of revenue. Consultations rose 2.6% to 174,440 and cash at bank was £8.3 million at 30 September 2026, after a £0.5 million payment received in advance.

Final Word

The three companies have each reported progress, from a regulatory designation to implant growth and higher revenue. Their next updates, including the coverage decision and pivotal data, will be the next markers.